iPLATO sold to Huma
Global health technology company Huma has acquired the UK-based patient engagement software provider, and developer of myGP app, iPLATO Healthcare for an undisclosed sum.
The two companies will continue to operate independently but will combine their expertise to enable a ‘more proactive, predictive and personalised care for patients’ across primary and secondary care. The aim is to advance digital-first delivery of care and remote patient monitoring for NHS patients.
iPLATO has been around for 15 years. Its patient engagement software covers a network of 26.6 million patients across nearly 3,000 NHS primary care organisations and its app service, myGP app, is one of the most downloaded medical apps in the UK.
According to the company, almost 2.4 million people in England use the myGP app to manage their health. iPLATO has also been instrumental in increasing uptake of NHS services, including IAPT services, cancer screenings, and health checks, resulting in up to 65% higher uptake of services communicated through the myGP platform, the company says.
Huma was founded in 2011. Today, its technology is used across the UK, Europe, US, Asia, and the Middle East and the company employs more than 150 staff. Huma’s platform supports digital ‘hospital at home’ for a range of use cases across different disease areas. In life sciences, it powers some of the world’s largest decentralized clinical trials and studies. It develops digital biomarkers, predictive algorithms, and real-world data from continuous patient monitoring to advance proactive, predictive care.
In a statement, Tobias Alpsten, chief executive of iPLATO Healthcare, said: “We are excited to offer leading remote patient monitoring capability from Huma to our primary care partners. We recently launched patient questionnaires on the myGP platform to enable patient data to be coded directly into the patients’ medical records.
“Combining tools like this with digital biomarkers can help create a world where we can tackle the biggest killers of our time – cancer, heart disease, and now, Covid-19. We see a time when data collection highlights people at high risk, so those individuals can be offered personalised screening, treatment, advice, support, and continual follow-up remotely – even alerting clinicians when patients need to be seen in person. Bringing our patient questionnaires together with Huma’s remote patient monitoring capability means that this future is not too far away.”
Dan Vahdat, chief executive and founder of Huma, added: “We are part of the movement using remote patient monitoring and digital biomarkers to transform healthcare. We’ve already shown how we can help clinicians care for more people whilst offering greater reassurance and oversight from monitoring even when patients are away from the clinic. But there is still so much more we can do.
“We want to introduce digital screening and our peer-reviewed cardiovascular and depression risk scores to give patients even more insight into their own health. Adding these capabilities to iPLATO’s patient engagement expertise gives us a fantastic opportunity to make a significant difference in primary care and help more patients to live longer fuller lives.”
Date published: January 20, 2022